# Advanced skin care solutions to improve the lives of your patients

## 3M™ Cavilon™ Skin Care Solutions

# Your best line of defence against conditions that can impede healing



You work hard to help your patients heal quickly and comfortably, but sometimes complications can slow their progress and negatively impact care costs and your facility's resources. Patient exposure to factors such as irritants, moisture, friction, shear and adhesives can lead to skin breakdown, including Moisture-Associated Skin Damage (MASD), Pressure Ulcer/Injury (PU/I) and Medical Adhesive-Related Skin Injury (MARSI).

## Moisture-Associated Skin Damage (MASD)

MASD is a term that describes several types of damage that occur when skin is exposed to excessive moisture and/or irritants. With over-hydration, the stratum corneum (outermost layer of the epidermis) becomes more permeable, skin pH becomes more alkaline and inflammation occurs.

Although pressure, shear, and friction are widely recognised as threats to skin integrity, the significant risk posed by frequent exposure to excessive moisture often goes unnoticed in causing skin breakdown. It's crucial for clinicians to remain vigilant in preserving optimal skin conditions and in early identification and treatment of Moisture-Associated Skin Damage (MASD) to prevent its progression and subsequent skin breakdown.

**Moisture and other fluids can lead to several types of MASD:**

- Incontinence-Associated Dermatitis (IAD)
- Peristomal Skin Damage
- Periwound Skin Damage
- Intertriginous Dermatitis (ITD)

**35%** of all IAD cases in the acute care setting are severe[1]

**41%** of nursing home residents may have IAD[2]

**77%** of patients with ostomies develop skin complications[3]




## Medical Adhesive-Related Skin Injury (MARSI)

Medical adhesives are a critical part of healthcare, but can cause Medical Adhesive-Related Skin Injury, or MARSI.

MARSI can cause pain, increase the risk of infection and delay healing – all of which can reduce a patient's/resident's quality of life.[6] Skin tears, skin stripping and tension blisters are common but avoidable examples of MARSI.




**of oncology patients developed MARSI** at their PICC insertion site over the course of two weeks.[4]

One study showed a

**21.4%**

**prevalence of MARSI in an acute care setting**. Prevalence may vary by care setting and patient risk factors.[5]




## Pressure Ulcer/Injury (PU/I)

Skin breakdown can lead to a pressure ulcer/injury which is localised damage to the skin and underlying soft tissue. Moisture, friction and shear are accepted as risk factors for pressure ulcer/injury development.

**3x**

**Patients with IAD are at an increased risk** of superficial sacral pressure ulcers/injuries with an odds ratio of 2.99.[7]




**of all pressure ulcers/injuries** occur at anatomical sites that overlay a bony prominence, such as the heel and sacrum.[8,9]

# Simplifying your skin integrity needs with proven solutions

Set your level of care apart with solutions that set themselves apart from competitive products in test after test. With an advanced skin protectant, novel barriers and other products that help maintain skin health, we have the comprehensive solutions you need to protect the skin that protects your patients.



## 3M™ Cavilon™ Advanced Skin Protectant

Cavilon Advanced Skin Protectant featuring innovative polymer-cyanoacrylate technology creates a highly durable, ultra-thin barrier that attaches to wet, weepy[10] or damaged skin and lasts up to seven days[11] – protecting patient skin.

## 3M™ Cavilon™ No Sting Barrier Film

With a unique terpolymer formula that delivers exceptional durability and flexibility, Cavilon No Sting Barrier Film is a gentle, effective and CHG-compatible solution for routine protection from friction, adhesives and bodily fluids, for up to 72 hours.[12]





## 3M™ Cavilon™ Durable Barrier Cream

Cavilon Durable Barrier Cream is a concentrated, durable, moisturising barrier cream formulated with polymer technology that resists wash-off, allows adhesives to adhere and will not block incontinence pads.[12]

## 3M™ Cavilon™ Continence Care Wipes

## 3M™ Cavilon™ Bathing & Cleansing Wipes

Cavilon Wipes provide your patients with an optimal way to feel both comfortable, clean and protected. You can gently wash and condition each part of the body and give protection where necessary with a low friction medical wipe. At the same time you will reduce the risk of cross contamination.

# Find your optimal 3M™ Cavilon™ Skin Care solution

IDEAL USE

## Manage damaged or broken skin

**Protect skin from:**

**Irritants**

Examples: Liquid stool, mixed faeces/urine, gastric fluid and chronic wound exudate

**Moisture, friction and/or shear**

- At-risk or compromised skin
- Routine protection

**Adhesives**

### 3M™ Cavilon™ Advanced Skin Protectant


Examples: Limited mobility, history of recurrent breakdown, fragile skin, macerated skin, heavy to copious exudate and prolonged exposure

### 3M™ Cavilon™ No Sting Barrier Film


**Moisture and dryness**

- Routine protection

### 3M™ Cavilon™ Durable Barrier Cream

# Finding the optimal solution for your skin integrity needs

| Incontinence-Associated Dermatitis (IAD) | Peristomal skin damage | Periwound skin damage | Intertriginous Dermatitis (ITD) | Pressure ulcer/injury | Medical Adhesive-Related Skin Injury (MARSI) |
|---|---|---|---|---|---|
| **Moisture-Associated Skin Damage (MASD)** | | | | | |
| **Manage damaged or broken skin** | | | | | |
| Manage IAD | Manage peristomal/ perifistular skin damage | Manage periwound skin damage (e.g. maceration), including compatibility of use under 3M acrylic negative pressure drapes | Manage superficial skin damage from moisture and friction | Manage superficial skin injury in difficult-to-dress locations | Manage superficial skin damage (e.g. stripping, skin tears) from adhesive use, including under vascular access dressings |
| **Protect at-risk skin** | | | | | |
| Protect intact skin especially in the presence of diarrhea or mixed incontinence | Protect skin around problem fecal or urinary stomas, fistulas or tracheostomies | Protect skin around at-risk wounds (e.g. heavily draining wounds such as diabetic foot ulcers, venous leg ulcers or infected wounds) | Protect intact and damaged skin from moisture and friction | Protect intact and damaged skin from moisture, friction or shear | Protect intact skin from adhesive products (e.g. tape, wound and vascular access dressings and ostomy products) |
| **Ideal for routine protection** | | | | | |
| Protect and moisturise intact skin for low-risk patients | | Protect intact skin for low-risk patients | Protect intact skin from moisture and friction | Protect intact skin from moisture, friction or shear | |

**For more information, contact your Solventum Account Representative or visit www.3M.co.uk/Cavilon**

## Ordering information

| | Code | Product | Size | Items/ box | Boxes/ case | Pharmacy code | Hospital code |
|---|---|---|---|---|---|---|---|
|  | 5050G | 3M™ Cavilon™ Advanced Skin Protectant* | 2.7ml applicator (sterile)* | 20 | 1 | | ELY985 |
| | 5050G4P | 3M™ Cavilon™ Advanced Skin Protectant* | 2.7ml applicator (sterile)* | 4 | 4 | 413-7899 | ELY842 |
| | 5051G | 3M™ Cavilon™ Advanced Skin Protectant* | 0.7ml applicator (sterile)* | 20 | 1 | 418-8215 | ELY841 |
| | 5051G4P | 3M™ Cavilon™ Advanced Skin Protectant* | 0.7ml applicator (sterile)* | 4 | 4 | 421-2536 | ELY85113 |
|  | 3343E | 3M™ Cavilon™ No Sting Barrier Film | 1ml wand (sterile) | 25 | 4 | | ELY038 |
| | 3343P | 3M™ Cavilon™ No Sting Barrier Film | 1ml wand (sterile) | 5 | 20 | 252-8941 | |
| | 3344E | 3M™ Cavilon™ No Sting Barrier Film | 1ml wipe (sterile) | 30 | 6 | 317-5692 | ELY190 |
| | 3345E | 3M™ Cavilon™ No Sting Barrier Film | 3ml wand (sterile) | 25 | 4 | | ELY039 |
| | 3345P | 3M™ Cavilon™ No Sting Barrier Film | 3ml wand (sterile) | 5 | 20 | 252-8958 | |
| | 3346E | 3M™ Cavilon™ No Sting Barrier Film | 28ml spray bottle | 12 | 1 | | ELY040 |
| | 3346P | 3M™ Cavilon™ No Sting Barrier Film | 28ml spray bottle | 1 | 12 | 252-8966 | |
|  | 3392GS | 3M™ Cavilon™ Durable Barrier Cream | 2g sachet | 20 | 12 | 288-2272 | ELY85115 |
| | 3391G | 3M™ Cavilon™ Durable Barrier Cream | 28g tube | 1 | 12 | 301-7480 | ELY85114 |
| | 3392G | 3M™ Cavilon™ Durable Barrier Cream | 92g tube | 1 | 12 | 277-1079 | ELY85116 |
|  | 9272 | 3M™ Cavilon™ Bathing & Cleansing Wipe | | 8 | 12 | | |
| | 9274 | 3M™ Cavilon™ Continence Wipe | | 8 | 12 | | |

*The fluid within the ampoule is non-sterile. The applicator is sterile if package is intact.


1. Gray M, Bartos S. Incontinence Associated Dermatitis in the Acute Care Setting: A Prospective Multi-site Epidemiologic Study. Presented at the 23rd Annual Meeting of the Wound Healing Society. 2013.
2. Nix D, Haugen V. Prevention and management of Incontinence-Associated Dermatitis. *Drugs Aging*. 2010. 27(6); 491–6.
3. Colwell JC, McNichol L, Boarini J. North America Wound, Ostomy, and Continence and Enterostomal Therapy Nurses Current Ostomy Care Practice Related to Peristomal Skin Issues. *J Wound Ostomy Continence Nurs.* 2017; 44(3): 257–261.
4. Zhao H, *et al.* Prevalence of medical adhesive-related skin injury at peripherally inserted central catheter insertion site in oncology patients. *J Vasc Access.* 2017 Nov 8:0. doi: 10.5301/jva.5000805.
5. Source: https://europepmc.org/abstract/med/15509110.
6. Cutting KF. Impact of adhesive surgical tape and wound dressing on the skin with reference to skin stripping. *J Wound Care.* 2008;157-158,160–162.
7. Demarre L, *et al.* Factors predicting the development of pressure ulcers in an at-risk population who receive standardized preventive care: secondary analyses of a multicentre randomised controlled trial. *J Adv Nurs.* 2015;71(2):391–403.
8. National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers: Clinical Practice Guideline. Emily Haesler (Ed.). Cambridge Media: Osborne Park, Western Australia; 2014.
9. VanGuilder, C., MacFarlane, G. D., & Meyer, S. (2008). Results of Nine International Pressure Ulcer Prevalence Surveys: 1989 to 2005. *Ostomy Wound Management,* 54(2).
10. Brennan, Mary R.; Milne, Catherine T.; Agrell-Kann, Marie; Ekholm, Bruce P. Clinical Evaluation of a Skin Protectant for the Management of Incontinence-Associated Dermatitis: An Open-Label, Nonrandomized, Prospective Study. *J of Wound, Ostomy & Continence Nurs.* 2017; 44(2):172–180.
11. Solventum data on file. EM-05-305812.
12. Issberner K, Schuren J, A Comparative study of the Skin Protectant performance of five Barrier Films. 3M Germany Laboratory, Neuss, Germany, 2004.
13. Hart J, (2002) Assessment of the incontinence pad blocking potential of Cavilon DBC compared with Sudocrem and Zinc and Castor oil. *Nursing Scotland* 2002, Issue July/August.


solventum


**Solventum UK**
KCI Medical Limited
Charnwood Campus
10 Bakewell Road
Loughborough
LE11 5RB
01509 611 611

**Solventum Ireland**
3M Healthcare EMEA Export Limited
2 Cumberland Place
Fenian Street
Dublin 2
D02 H0V5
1 800 320 500